[A phase II study of 590-S (1-phthalidyl-5-fluorouracil) in patients with breast cancer--multi-center cooperative study--Cooperative Study Group of 590-S in Breast Cancer].

Abstract

A phase II clinical study involving 16 institutions was performed for the treatment of breast cancer with 590-S, a new masked fluoropyrimidine derivative. A dose of 900 mg/day was administered orally for more than 4 weeks. Out of 33 cases enrolled, 18 were completely recorded and evaluable. The response rate was 33.3%: 2 CR and 4 PR. It was noteworthy that, out of 12 cases previously treated with other 5-FU derivatives, 5 cases (41.7%) were judged as effective. Of 26 cases, side effects were observed in 8 (30.8%). All of these were gastrointestinal disorders such as nausea, vomiting, and loss of appetite. 590-S is considered to be a useful antitumor agent. However, further investigation will be required.

• Authors: T Taguchi, T Terasawa
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 14 Issue 2 Pg. 467-71 (Feb 1987) ISSN: 0385-0684 [Print] Japan
• PMID: 3813575 (Publication Type: English Abstract, Journal Article)

Chemical References

• 1-phthalidyl-5-fluorouracil
• Fluorouracil

Topics

• Administration, Oral
• Adult
• Aged
• Breast Neoplasms (drug therapy)
• Drug Administration Schedule
• Drug Evaluation
• Female
• Fluorouracil (administration & dosage, analogs & derivatives, therapeutic use)
• Humans
• Middle Aged